Patient Condition
The patient developed weakness in both lower limbs since the age of 51, and was diagnosed with ALS (limb onset) at the age of 52. At the time of diagnosis, ALSFRS-R was 33, FVC was 74%, and both lower limb muscle strength was grade 3+. The progress rate is moderate (0.9 points per month). Enrolled into a clinical trial of mesenchymal stem cells (MSC).
Treatment Timeline
| Phase | Details | Date |
|---|
| Stem cell therapy preparation and first infusion | | |
| Rehabilitation and Functional Assessment | | |
| long-term follow-up | | |
Treatment Outcome
| before | ALSFRS-R 33, monthly drop 0.9, FVC 74%, weakness of both lower limbs |
|---|
| after | ALSFRS-R 29 points, 2-year decrease of 4 points (delay of 78%), FVC 68%, walking aid assisted walking |
|---|
| highlight | Intrathecal injection of autologous BM-MSC combined with Ziluzole delayed progression by 78%, stem cell therapy showed neuroprotective potential |
|---|